Availability, Current issues, and Anticipation Training for Clinician-Patient Communication in Palliative Care: Learning and Doing or Learning by Doing?

S. Kumar,M. Goyal,V. Sisodia,Vijaya K. Kumar

DOI: https://doi.org/10.4103/0973-1075.138405

2014-09-01

Indian Journal of Palliative Care

Abstract:

What problem does this paper attempt to address?

Seasonal variation of anti‐PD‐1 outcome in melanoma—Results from a Dutch patient cohort

J. S. W. Borgers,F. H. Burgers,A. Schina,O. J. Van Not,A. J. M. Eertwegh,C. U. Blank,M. J. B. Aarts,F. W. P. J. Berkmortel,J. W. B. Groot,G. A. P. Hospers,E. Kapiteijn,D. Piersma,R. S. Rijn,A. M. Stevense‐den Boer,A. A. M. Veldt,G. Vreugdenhil,M. J. Boers‐Sonderen,M. W. J. M. Wouters,K. P. M. Suijkerbuijk,J. V. Thienen,J. B. A. G. Haanen,O. J. Van Not

DOI: https://doi.org/10.1111/pcmr.13117

2023-08-10

Abstract:Despite the improved survival rates of patients with advanced stage melanoma since the introduction of ICIs, many patients do not have (long‐term) benefit from these treatments. There is evidence that the exposome, an accumulation of host‐extrinsic factors including environmental influences, could impact ICI response. Recently, a survival benefit was observed in patients with BRAF wild‐type melanoma living in Denmark who initiated immunotherapy in summer as compared to winter. As the Netherlands lies in close geographical proximity to Denmark and has comparable seasonal differences, a Dutch validation cohort was established using data from our nationwide melanoma registry. In this study, we did not observe a similar seasonal difference in overall survival and are therefore unable to confirm the Danish findings. Validation of either the Dutch or Danish findings in (combined) patient cohorts from other countries would be necessary to determine whether this host‐extrinsic factor influences the response to ICI‐treatment.

dermatology,oncology,cell biology
Trends in epidemiology and primary treatment of anal squamous cell carcinoma in the Netherlands (1990-2021)

Vincent K Y Ho,Charlotte L Deijen,Birgit Hemmes,Felice N van Erning,Petur Snaebjornsson,Baukelien van Triest,Brechtje A Grotenhuis

DOI: https://doi.org/10.1002/ijc.34811

2024-05-01

Abstract:A rapid increase in the incidence of anal squamous cell carcinoma (SCC) was reported in several countries over the past decades. This study assessed trends in epidemiology and primary treatment over a 32-year period (1990-2021) using the Netherlands Cancer Registry. The study population included 4273 patients, 44.2% male and 55.8% female (median age 63 years). The age-standardised incidence rate (European Standardised Rate, ESR) increased from 0.5 to 1.6 per 100,000, which entailed an average annual percentage change (AAPC) of 5.0% (95% confidence interval [CI]: 4.5%-5.8%). While incidence among females increased continuously over the total period (AAPC 4.9%; 95%CI: 4.4%-5.6%), to 1.8 per 100,000 ESR in 2021, incidence among males increased until 2016 (annual percentage change [APC] of 6.3%; 95%CI: 5.6%-10.7%), after which it seemed to stabilise (APC -2.1%; 95%CI: -16.8%-4.5%). Significant trends were also observed in distribution of age, tumour stage and primary treatment modalities. Five-year relative survival (RS) was estimated using the Pohar-Perme estimator, and this improved from 56.1% in 1990-1997 (95%CI: 49.3%-62.4%) to 67.9% in 2014-2021 (95%CI: 64.7%-70.9%), but remained poor for stage IV disease. Evaluation through a multivariable Poisson regression model demonstrated diagnosis in the most recent period to be independently associated with better RS, in addition to female sex, younger age, early disease stage and any treatment. In conclusion, the rising incidence of anal SCC seems to decline in males, but not in females, and advances in diagnostics and therapeutic management have likely contributed to improved prognosis.
P070 The epidemiology of skin cancer in Greater Manchester 2017–22: a retrospective cohort study using primary care records

Lana Y H Lai,Ben W M Sim,Tracey Farragher,Brian McMillan,Emma McMullen,Zoe C Venables,Zenas Z N Yiu

DOI: https://doi.org/10.1093/bjd/ljae090.097

IF: 11.113

2024-06-28

British Journal of Dermatology

Abstract:Abstract Skin cancer is the commonest cancer in the UK, with increasing incidence, creating a significant workload for dermatology departments. Greater Manchester is one of the most populous areas in the UK, and understanding the regional skin cancer trends is vital for healthcare service planning and public health interventions. The Greater Manchester Care Record (GMCR) holds data from 99.5% of general practices on > 3 million registered patients (Watkinson RE, Williams R, Gillibrand S et al. Ethnic inequalities in COVID-19 vaccine uptake and comparison to seasonal influenza vaccine uptake in Greater Manchester, UK: a cohort study. PLOS Med 2022; 19: e1003932). It was approved for research access for COVID-19 response analysis, which allowed this opportunity to understand the epidemiology of skin cancer in Greater Manchester. This retrospective observational cohort study of the GMCR included cases of basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC) and malignant melanoma (MM) registered between January 2017 and December 2022. We calculated the crude incidence rate (IR) per 100 000 person-years by skin cancer type, age group and sex. To avoid duplication, we restricted cases to a timeframe of at least 2 weeks before a subsequent case was counted, based on expert advice and review of the data. The denominator was the summation of 1 year of follow-up for each registered patient as of December each year. We compared the IR from GMCR to the national cancer registry IR from the ‘Get Data Out’ skin initiative. We identified 42 370 cases of BCC, 7503 cSCC and 7924 MM between 2017 and 2022, with respective median (interquartile range) ages at diagnosis of 73.3 years (62.3–80.9), 73.6 years (62.2–81.9) and 62.0 years (49.1–73.8); the majority (> 87%) of the population was White. The IR ranged from the lowest at 185, 44 and 36 per 100 000 person-years in 2020 (coinciding with the early stages of the pandemic) to the highest at 265 (2022), 35 (2019) and 54 (2022) per 100 000 person-years for BCC, cSCC and MM, respectively. The incidence rate ratios (95% confidence interval) for 2020 vs. 2019 were 0.79 (0.76–0.81), 0.98 (0.91–1.06) and 0.87 (0.80–0.94) for BCC, cSCC and MM, respectively. The male-to-female ratio was around 1 for BCC and cSCC until age 70 years, after which there was an increasing male preponderance, while for MM the same divergence started at age 50 years. We report lower IRs for both BCC and cSCC compared with England, and a higher IR for MM. We present the epidemiology of skin cancer in Greater Manchester from a novel primary care dataset, showing reductions in IR during 2020 of 21%, 2% and 13% for BCC, cSCC and MM, respectively. We report a lower than expected IR of cSCC, which is a likely underestimate and requires further investigation.

dermatology
Seasonal variations in the diagnosis of the top 10 cancers in Korea: A nationwide population-based study using a common data model

Jin Young Yoon,Min Seob Kwak,Ha Il Kim,Jae Myung Cha

DOI: https://doi.org/10.1111/jgh.15634

Abstract:Background and aim: A better understanding of seasonal variations in cancer diagnosis may be the first step toward optimal resource distribution in the National Cancer Screening Program (NCSP). This study aimed to identify seasonal variations in the diagnosis of the top 10 major cancers in Korea. Methods: We conducted a retrospective, observational cohort study in participants aged ≥ 20 years between 2012 and 2016 from the Health Insurance Review and Assessment-National Patient Sample database, previously converted to a common data model. We assessed the overall seasonal variations in the 10 major cancers. Results: We analyzed the following top 10 cancers: stomach (n = 3435), colorectal (n = 5368), liver (n = 7605), pancreatic (n = 2946), gallbladder (n = 899), lung (n = 1598), prostate (n = 2897), thyroid (n = 1966), breast (n = 1313), and kidney (n = 668) cancers. All cancers showed similar seasonal variations in diagnosis, with a significant winter peak. A winter peak in diagnosis was observed for NCSP-covered cancers, such as stomach, colon, liver, and breast cancers, as well as other cancers not covered by the NCSP. The winter peak for cancer diagnosis was the highest for breast cancer (74.4%) followed by thyroid (51.0%) and stomach cancers, whereas it was the lowest for pancreatic cancer followed by prostate and colorectal cancers. Conclusions: Significant seasonal variations were found in the diagnosis of the top 10 major cancers, with a winter peak, which may be explained by the participants' behavior pattern with respect to the NCSP. Our findings suggest that trading off of NCSP healthcare resources between winter and other seasons may be beneficial.
O13 42 590 fewer skin tumours diagnosed in England during the 2020 COVID pandemic: greatest reductions in melanoma in situ , stage I melanomas and basal cell carcinomas

Omsin Srimudkul,Zoe C Venables,Nick J Levell,Khaylen Mistry,Birgitta Van Bodegraven

DOI: https://doi.org/10.1093/bjd/ljae090.013

IF: 11.113

2024-06-28

British Journal of Dermatology

Abstract:Abstract During the early COVID-19 pandemic, there was a decline in most cancer diagnoses. The aim of this study was to ascertain the extent and impact of this on skin cancer subtypes in England. This national retrospective cohort study identified all skin tumour cases diagnosed in 2019 and 2020 in England from the National Disease Registration Service ‘Get Data Out’ project. Incidence rate ratios (IRRs) with 95% confidence intervals (CIs) and Poisson regression analysis were used to compare crude incidence rates (CIR) per 100 000 person-years (PY) in 2020 vs. 2019. In 2019, there were 233 717 skin tumours registered in England; this reduced to 191 127 (IRR 0.81, 95% CI 0.80–0.81, P < 0.001) in 2020. A year prior to the pandemic, there were 15 355 (CIR 27.3 PY) melanomas, 7135 (CIR 12.7 PY) melanomas in situ, 48 112 (CIR 85.5 PY) cutaneous squamous cell carcinomas (cSCCs), 159 178 (CIR 283 PY) basal cell carcinomas (BCCs) and 363 (CIR 0.65 PY) Merkel cell carcinomas (MCCs). When comparing incidence rates for 2020 vs. 2019, significant reductions (P < 0.001) were seen in all tumours except MCC: melanoma (IRR 0.81, 95% CI 0.79–0.83), melanoma in situ (IRR 0.65, 95% CI 0.63–0.68), cSCC (IRR 0.94, 95% CI 0.93–0.96), BCC (IRR 0.78, 95% CI 0.78–0.79) and MCC (IRR 0.93, 95% CI 0.80–1.08). For melanoma by stage, there were 8940 (CIR 22.6 PY) stage I, 2441 (CIR 6.18 PY) stage II, 1004 (CIR 2.54 PY) stage III, 385 (CIR 0.97 PY) stage IV and 2187 (CIR 5.53 PY) stage ‘unknown’ in 2019. The IRR for 2020 vs. 2019 showed significant reductions (P < 0.001) for stage I (IRR 0.76, 95% CI 0.73–0.78) and stage ‘unknown’ melanomas (IRR 0.67, 95% CI 0.62–0.71), while changes were not significant for all other stages. During the 2020 COVID pandemic, there was a 19% reduction in diagnosed skin tumours in England. There was a differential impact between tumour types and stages, with the greatest reduction seen in melanoma in situ (−35%), stage I melanoma (−24%) and BCC (−22%), compared with MCC (−7%), cSCC (−6%) and stage II+ melanoma (+2%). The improvement to staging data in 2020 (−33% ‘unknown’ stage melanomas) limits interpretation, but these account for < 15% of cases of melanoma. It is hypothesized that symptomatic and slow-growing tumours were not prioritized by patients and/or clinicians, potentially resulting in worse patient outcomes and increased burden on health services. This indicates a need for more time to study the impact of delayed diagnosis on survival, better public education on skin cancer recognition, and improved service provision during national emergencies.

dermatology
Seasonal variation in effect of anti‐PD‐1 initiation on overall survival among patients with advanced melanoma

Eva Ellebaek,Aimilia Schina,Henrik Schmidt,Charlotte Aaquist Haslund,Lars Bastholt,Inge Marie Svane,Marco Donia

DOI: https://doi.org/10.1111/pcmr.13072

2022-10-21

Abstract:Background Melanoma is a highly immunogenic cancer, and circannual rhythms influence the activity of the immune system. Methods We retrospectively collected information on all cases with metastatic melanoma (ocular melanoma excluded) that initiated treatment with BRAF‐inhibitor‐based therapy (BRAFi) or anti‐PD‐1 monotherapy (PD‐1). Cases where divided in two groups based on treatment initiation in the summer half‐year (April to September) or winter half‐year (October to March). Results We collected a total of 1054 (BRAF‐i) and 1205 (PD‐1) patient cases. Median follow‐up was 39.7 (BRAFi) and 47.5 (PD‐1) months. We did not observe differences in outcomes across patients who were treated in summer versus winter in the BRAFi cohort. Furthermore, we did not observe significant differences in ORR, CRR and PFS in the PD‐1 cohort. However, in patients with BRAF wild‐type disease of the PD‐1 cohort, treatment initiation in summer was associated with an improved OS (mOS 39.7 months (summer) versus 21.3 months (winter); HR 0.70, 95% CI 0.57‐0.86, p=0.0007). This result remained robust to multivariable proportional hazards adjustment (HR 0.70, 95% CI 0.57‐0.87, p=0.001). Conclusions Initiation of immunotherapy in summer is associated with prolonged survival in patients with BRAF wild‐type melanoma living in Denmark.

dermatology,oncology,cell biology
Time trends in incidence and mortality of cutaneous melanoma in Germany

C. Garbe,U. Keim,T. K. Eigentler,T. Amaral,A. Katalinic,B. Holleczek,P. Martus,U. Leiter

DOI: https://doi.org/10.1111/jdv.15322

2019-04-17

Journal of the European Academy of Dermatology and Venereology

Abstract:OBJECTIVES: To characterize incidence and mortality trends of cutaneous melanoma (CM) in Germany to extrapolate these data until 2030.METHODS: We evaluated data from the Centre for Cancer Registry Data (1999-2012) and from the Saarland Cancer Registry (1970-2012). Age-standardized (according to the European Standard Population, WHO 1976) incidence and mortality rates [age-standardized incidence rates (ASIRs) and age-standardized mortality rates (ASMRs)] and crude incidence and mortality rates [crude incidence rates (CIRs) and crude mortality rates (CMRs)] were analysed.RESULTS: In entire Germany, ASIRs increased by 55% to 19.2 and CIRs by 77% to 26.0 new cases per 100 000 from 1999 to 2012. ASMRs remained stable, whereas CMR increased by 58% to 4.1 for males and by 30% to 3.0 for females per 100 000. In the Federal State of Saarland, ASIRs increased more than four-fold to 13.1, CIRs increased six-seven fold to 18.5/100 000 from 1970 to 2012. In the same period, ASMRs increased three-fold in males and two-fold in females to 2.5 and 1.6, whereas CMRs increased 5.5-fold in males and 3.5-fold in females to 3.9 and 3.2/100 000, mainly caused by steep increases of CIRs and CMRs in age groups ≥60 years. Projected CIRs will rise to 44-46 for males and 38-40 for females in 2030. Steepest increases were extrapolated for patients ≥60 years, especially for males, but are also expected for age groups of 40-59 years. In contrast, CIRs are anticipated to stabilize for subjects <40 years.CONCLUSIONS: There is a constant increase in incidence and mortality rates for CM in Germany. As the German population is ageing and the current population has already accumulated high levels of UV exposure, a further increase in melanoma incidence is projected for the future without signs of levelling-off.

dermatology
Incidence of Nonmelanoma Skin Cancers in Alberta, Canada, From 2007 to 2018

Daniel B Chambers,Sunita Ghosh,Muba S Taher,Thomas G Salopek,Daniel B. Chambers,Muba S. Taher,Thomas G. Salopek

DOI: https://doi.org/10.1177/12034754241232677

2024-02-21

Journal of Cutaneous Medicine and Surgery

Abstract:Journal of Cutaneous Medicine and Surgery, Ahead of Print. Background:Nonmelanoma skin cancer (NMSC) is the most common malignancy affecting Caucasian populations and has been seeing steady increases in incidence globally for decades. Our previous study (from Alberta, Canada) had shown a plateau in the incidence rates for NMSC. This contrasts with data from other regions within Canada and throughout the world that indicated a continued increase in incidence rates of NMSCs.Objectives:The objective of this study was to provide an update on the trends in incidence of NMSC in Alberta, Canada, from 2007 to 2018.Methods:A retrospective analysis of patients from Alberta diagnosed with NMSC from 2007 to 2018 inclusive was conducted with data retrieved from Alberta Cancer Registry. Sex-, age-, anatomical location-, NMSC subtype-, stage-specific incidence rates and trends were examined.Results:From 2007 to 2018, overall incidence rates of NMSC increased by 36%. Invasive squamous cell carcinoma (SCC) and in situ SCC demonstrated the most significant increase, invasive SCC [annual percentage change (APC) 3.48, P = .014] and in situ SCC (APC 5.61, P = .0001). In addition, we were able to determine that females had the most significant increases in NMSC incidence rates from 2007 to 2018 particularly invasive SCC (APC 3.03, P = <.0001) and in situ SCC (APC 5.08, P = <.0001).Conclusions:After initial levelling of NMSC incidence in Alberta in the early part of 21st century, the incidence of NMSC continues to increase over the past decade. The reasons for this change are not clear and likely multifactorial.

dermatology
Does sex matter? Temporal analyses of melanoma trends among men and women suggest etiologic heterogeneity

Catherine M. Olsen,Nirmala Pandeya,Adalberto Miranda-Filho,Philip S. Rosenberg,David C. Whiteman

DOI: https://doi.org/10.1016/j.jid.2024.05.011

IF: 7.59

2024-06-21

Journal of Investigative Dermatology

Abstract:The incidence and distribution of cutaneous melanoma differs between the sexes, but it is unclear whether these differences have been constant through time or across generations. We compared incidence trends by age, sex, and anatomic site by analyzing long-term melanoma data (1982-2018) in three populations residing at high-, moderate- and low- ambient sun exposure: Queensland, Australia; United States White; Scotland. We fit age-period-cohort models and compared trends in the male-to-female...

dermatology
O09 Cutaneous squamous cell carcinoma survival in England 2004–2020: a national retrospective observational cohort study

Birgitta van Bodegraven,Sally Vernon,Chloe Bright,Thomas Higgins,Polly Jeffrey,Anna Ascott,Sonia Gran,Catherine Harwood,George Millington,Charlotte Proby,Zoe C Venables

DOI: https://doi.org/10.1093/bjd/ljae090.009

IF: 11.113

2024-06-28

British Journal of Dermatology

Abstract:Abstract Cutaneous squamous cell carcinoma (cSCC) is the second most common type of skin cancer, with 45 585 cSCCs recorded in England in 2020. cSCC net survival is published in the National Disease Registration Service (NDRS) Get Data Out programme and is reported as 90% at 5 years, similar to melanoma, breast cancer and prostate cancer, despite lower mortality rates for cSCC. The aim of this national retrospective cancer registry cohort study of NDRS data was to clarify published survival estimates by reporting the overall and cause-specific survival of people diagnosed with cSCC. Diagnoses of a first-ever cSCC tumour during 2004–20 were included. The end of follow-up was 5 January 2022. Immunosuppression was defined as a history of haematological malignancy, HIV, end-stage renal disease, or solid organ transplant, as identified in the Hospital Episode Statistics and NDRS cancer registrations. Cause-specific deaths were defined as the presence of the International Classification of Diseases 10th Revision code ‘C44’ (nonmelanoma skin cancer) on the death certificate. This work includes patient data collated by NDRS. Kaplan–Meier survival was estimated. Net survival was estimated using the Pohar Perme estimator. Cox proportional hazard regression was used to model associations with patient characteristics, including immunosuppression history and subsequent tumour development. In total, 415 236 first-ever cSCC tumours were identified, of which 415 166 were included in the survival analyses. The median age at diagnosis was 78 years (interquartile range 71–85) and 61.7% of patients (n = 256 163) were male. Overall, 26 200 (6.3%) were identified as immunosuppressed. In total, 230 533 deaths were observed, of which 13 270 (5.8%) were cause-specific deaths. Other commonly recorded causes of death included pneumonia (n = 60 440), chronic ischaemic heart disease (n = 55 779) and senility (n = 50 612). The 5-year Kaplan–Meier survival was 63.7%, 95% confidence interval (CI) 63.6–63.9. A significant survival difference was observed between men and women (χ2-test P < 0.001), with median survival of 7.3 years (95% CI 7.3–7.4) and 8.1 years (95% CI 8.1–8.2), respectively. Associations between overall death and history of immunosuppression (hazard ratio 1.62, 95% CI 1.60–1.65) and overall death and second cSCC tumour (hazard ratio 1.43, 95% CI 1.41–1.44) were observed in univariate models and remained significant in adjusted models. The 3-year net survival rates were 93.7% (95% CI 93.2–94.1) and 94.1% (95% CI 93.7–94.5) for tumours diagnosed in 2013–15 and 2016–18, respectively. cSCC Kaplan–Meier median survival by sex (male 7.3 years, female 8.1 years) is lower than the expected population median survival at 78 years, which is 9.5 years for men and 11.0 years for women. This national study provides detailed information on cSCC survival in England over a 15-year period and provides information to patients and clinicians on expected survival after diagnosis.

dermatology
Increasing melanoma incidence with unchanged mortality: more sunshine, better treatment, increased diagnostic activity, overdiagnosis or lowered diagnostic threshold?

Jesper Bo Nielsen,Ivar Sønbø Kristiansen,Subash Thapa

DOI: https://doi.org/10.1093/bjd/ljae175

IF: 11.113

2024-04-24

British Journal of Dermatology

Abstract:Abstract Background Increasing melanoma incidence with less increasing mortality is observed in several countries. This discrepancy is not well understood. Objective In this study, our aim was to discuss factors (UV exposure, melanoma treatment, diagnostic activity, overdiagnosis, pathologists’ diagnostic threshold and clinicians’ propensity to remove suspect skin lesions) that may influence melanoma incidence and mortality in Denmark. Methods This was a register study with the number of melanocyte-related lesions and melanoma mortality based on comprehensive national pathology and mortality databases for the period 1999-2019. We investigated melanocyte-related diagnoses and mortality in a population of 5.5 million with national health care system. Age adjusted melanoma mortality and age-adjusted incidence of benign nevi, atypical lesion, or melanoma-in-situ and of invasive melanoma were computed for data analysis. Results In total 1,434,798 biopsies were taken from 704,682 individuals (65% female). Mean age at biopsy was 39.8 years in men and 37.6 in women. In men and women, the incidence of invasive melanoma increased by 87% during the period 1999-2011. During the subsequent period it increased by 9% in men but remained unchanged in women. The incidence of melanoma in-situ increased by 476% in men and 357% in women during the study period, while the increases for atypical melanocytic lesions were 1928% and 1686%, respectively. Biopsy rates increased by 153% in men and 118% in women from 1999 through 2011 but fell by 20% in men and 22% in women during the subsequent period. Mortality varied slightly from year to year without any significant time trend for men or women. We identified no evidence of increased UV exposure over the latest 30 years in Denmark. Immunotherapy of advanced melanoma was introduced in Denmark in 2010 and came in general use in 2014. Conclusions Comprehensive national data demonstrate increasing melanoma incidence correlated with increasing biopsy rates, but with no change in mortality. Previously suggested explanations for such a trend are lowered threshold of melanoma diagnosis among pathologists, increased diagnostic activity in the presence of overdiagnosis and improved melanoma treatment. Because the study is observational and because we have more explanatory factors than outcomes, the findings do not warrant conclusions about causal relationships.

dermatology
Sinonasal mucosal melanoma in The Netherlands between 2001 and 2021: a clinical and epidemiological overview of 320 cases

W. F. Julius Scheurleer,Lise J. van de Velde,Lot A. Devriese,Mischa de Ridder,Marieke W. J. Louwman,Gerben E. Breimer,Remco de Bree,Boukje A. C. van Dijk,Johannes A. Rijken

DOI: https://doi.org/10.1007/s00405-024-08717-7

2024-05-18

European Archives of Oto-Rhino-Laryngology

Abstract:Abstract Purpose Sinonasal mucosal melanoma (SNMM) is a rare malignancy, characterised by high (local) recurrence rates and poor survival. Comprehensive understanding of tumour etiology is currently lacking, which complicates adequate tumour treatment. Besides examining trends in incidence, this study aims to assess the association between clinical characteristics, treatment practices and patient outcomes, with the objective of establishing a baseline from which SNMM management can be enhanced. Methods All newly diagnosed SNMM cases in The Netherlands between 2001 and 2021 were included using data from The Netherlands Cancer Registry (NCR). Results A total of 320 patients were included. The annual incidence rate for the overall population was stable over the inclusion period with an annual percentage change (APC) of only − 0.01%. The 5-year overall survival (OS) and relative survival (RS) were 24.5 and 32.4%, respectively. Relative survival did not increase over time. The addition of adjuvant radiotherapy to surgery was not associated with a higher OS and RS compared to surgery alone. Conclusion Sinonasal mucosal melanoma is a rare disease with stable incidence rates in the Netherlands between 2001 and 2021. There has been no improvement in survival over the course of the inclusion period. The study reaffirms that adjuvant radiotherapy does not seem to improve patient outcomes. Given the generally poor outcomes for SNMM patients, novel therapeutic options ought to be considered in order to improve care.

otorhinolaryngology
Envelopes and Geometrical Covers of Side-Payment Games and Their Market Representations

Philippe Artzner,C. d'Aspremont,L. Gérard-Varet

DOI: https://doi.org/10.1287/moor.11.1.19

IF: 2.215

1986-02-01

Mathematics of Operations Research

Abstract:This paper deals with issues concerning the core as a solution concept for games in coalitional form as well as the use of these games in representing economies of a certain formal type. Side-payment games are imbedded in the more general class of no-side-payment games. It is shown that to a given side-payment game having an empty core one may associate two different no-side-payment games with the same nonempty core: the “envelope” and the “geometrical cover.” The discrepancy is explained in terms of market games.
Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy

Aljosja Rogiers,Florentia Dimitriou,Irene Lobon,Catriona Harvey,Ismael A Vergara,Ines Pires da Silva,Serigne N Lo,Richard A Scolyer,Matteo S Carlino,Alexander M Menzies,Georgina V Long

DOI: https://doi.org/10.1016/j.ejca.2023.113506

Abstract:Background: Immune checkpoint inhibitors are frequently associated with the development of immunotherapy-related adverse events (irAEs). The exact etiology, including the role of environmental factors, remains incompletely understood. Methods: We analyzed the records of 394 melanoma patients from three centers (northern and southern hemisphere). Patients had received at least one cycle of anti-PD-1/anti-CTLA-4 with a minimum follow-up of 3 months. We study the distribution and time to irAEs onset throughout the calendar year. Results: 764 irAEs were recorded; the most frequent were skin rash (35%), hepatitis (32%) and colitis (30%). The irAEs incidence was the highest in autumn and winter, and the ratio for the 'number of irAEs' per 'therapies commenced' was the highest in winter and lowest in summer (2.4 and 1.7, respectively). Season-specific patterns in the time of irAEs onset were observed for pneumonitis (shorter time to onset in autumn, p = 0.025), hepatitis (shorter time to onset in spring, p = 0.016) and sarcoid-like immune reaction (shorter time to onset in autumn, p = 0.041). Season-specific patterns for early-onset irAEs were observed for hepatitis (spring, p = 0.023) and nephritis (summer, p = 0.017). Early-onset pneumonitis was more frequent in autumn-winter (p = 0.008) and early-onset nephritis in spring-summer (p = 0.004). Conclusions: Environmental factors that are associated with particular seasons may contribute to the development of certain irAEs and suggest the potential effect of environmental triggers. The identification of these factors may enhance preventive and therapeutic strategies to reduce the morbidity of irAEs.
Nationwide Trends in the Incidence of Melanoma and Non-melanoma Skin Cancers from 1999 to 2014 in South Korea

Chang-Mo Oh,Hyunsoon Cho,Young-Joo Won,Hyun-Joo Kong,Yun Ho Roh,Ki-Heon Jeong,Kyu-Won Jung

DOI: https://doi.org/10.4143/crt.2017.166

IF: 5.036

2018-07-15

Cancer Research and Treatment

Abstract:PURPOSE: This descriptive study was aimed to examine trends in the incidence of melanoma and nonmelanoma in South Korea.MATERIALS AND METHODS: The nationwide incidence data for melanoma and non-melanoma skin cancer was obtained from the Korea Central Cancer Registry. Age-standardized rates were calculated and analyzed, using a Joinpoint regression model.RESULTS: The incidence of basal cell carcinoma has increased dramatically both in men (average annual percentage change [AAPC], 8.0 [95% confidence interval (CI), 6.0 to 10.1]) and women (AAPC, 9.0 [95% CI, 7.5 to 10.4]). Squamous cell carcinoma has also steadily increased both in men (AAPC, 3.3 [95% CI, 2.6 to 4.0]) and women (AAPC, 6.8 [95% CI, 5.3 to 8.4]). Cutaneous melanoma increased continuously from 1999 to 2014 inwomen (AAPC, 3.5 [95% CI, 2.4 to 4.6]), whilst rapidly increasing in men until 2005 (APC, 7.9 [95% CI, 2.4 to 13.7]) after which no increase has been observed (APC, ‒0.2 [95% CI, ‒2.3 to 2.0]).CONCLUSION: The incidence rates of melanoma and non-melanoma skin cancer have increased over the past years, with the exception of melanoma in men. Further studies are required to investigate the reasons for the increased incidence of these skin cancers in South Korea.

oncology
Global, regional and national incidence, mortality and disability‐adjusted life‐years of skin cancers and trend analysis from 1990 to 2019: An analysis of the Global Burden of Disease Study 2019

Wei Zhang,Wen Zeng,Aofei Jiang,Zhi He,Xiaoping Shen,Xian Dong,Jianglong Feng,Hongguang Lu

DOI: https://doi.org/10.1002/cam4.4046

IF: 4.711

2021-06-09

Cancer Medicine

Abstract:BackgroundInformation about global and local epidemiology and trends of skin cancers is limited, which increases the difficulty of cutaneous cancer control. MethodsTo estimate the global spatial patterns and temporal trends of skin cancer burden. Based on the GBD 2019, we collected and analyzed numbers and age-standardized rates (ASR) of skin cancer incidence, disability-adjusted life years (DALYs) and mortality (ASIR, ASDR, and ASMR) in 204 countries from 1990 through 2019 were estimated by age, sex, subtype (malignant skin melanoma [MSM], squamous-cell carcinoma [SCC], and basal-cell carcinoma [BCC]), Socio-demographic Index (SDI), region, and country. Temporal trends in ASR were also analyzed using estimated annual percentage change. ResultsGlobally, in 2019, there were 4.0 million BCC, 2.4 million SCC, and 0.3 million MSM. There were approximately 62.8 thousand deaths and 1.7 million DALYs due to MSM, and 56.1 thousand deaths and 1.2 million DALYs were attributed to SCC, respectively. The men had higher ASR of skin cancer burden than women. The age-specific rates of global skin cancer burden were higher in the older adults, increasing trends observed from 55 years old. Geographically, the numbers and ASR of skin cancers varied greatly across countries, with the largest burden of ASIR in high SDI regions. However, an unexpected increase was observed in some regions from 1990 to 2019, such as East Asia, and Sub-Saharan Africa. Although there was a slight decrease of the ASMR and ASDR, the global ASIR of MSM dramatically increased, 1990–2019. Also, there was a remarkable increase in ASR of BCC and SCC burden. ConclusionsSkin cancer remains a major global public health threat. Reducing morbidity and mortality strategies such as primary and secondary prevention should be reconsidered, especially in the most prevalent and unexpected increased regions, especially for those areas with the greatest proportions of their population over age 55.

oncology
Patient presentation, skin biopsy utilization and cutaneous malignant melanoma incidence and mortality in northern Italy: Trends and correlations

Lauro Bucchi,Silvia Mancini,Federica Zamagni,Emanuele Crocetti,Luigino Dal Maso,Stefano Ferretti,Flavia Baldacchini,Orietta Giuliani,Alessandra Ravaioli,Rosa Vattiato,Angelita Brustolin,Giuseppa Candela,Simona Carone,Giuliano Carrozzi,Rossella Cavallo,Ylenia Maria Dinaro,Margherita Ferrante,Silvia Iacovacci,Guido Mazzoleni,Antonino Musolino,Roberto Vito Rizzello,Diego Serraino,Annibale Biggeri,Ignazio Stanganelli,Fabio Falcini,Francesca Bella,Claudia Cirilli,Simonetta Curatella,Rosario Tumino,Claudia Galluzzo,Fabrizio Stracci,Alessio Gili,Antonella Ippolito,Maria Michiara,Caterina Oriente,Silvano Piffer,Tiziana Scuderi,Federica Toffolutti,Fabio Vittadello,

DOI: https://doi.org/10.1111/jdv.18635

2022-10-20

Journal of the European Academy of Dermatology and Venereology

Abstract:BACKGROUND: The global increase in incidence of cutaneous malignant melanoma (CMM) occurring in the past decades has been partly attributed to increased diagnostic scrutiny of early lesions, with a potential phenomenon of overdiagnosis. The reported positive linear relation between skin biopsy rate and incidence of early CMM is compatible with this hypothesis.OBJECTIVES: We explored the ecological association between the trends in annual dermatologic office visit rates, skin biopsy rates, incidence rates of in situ and invasive CMM by tumour thickness category, and CMM mortality rates in the Emilia-Romagna Region (northern Italy).METHODS: Four cancer registries covering a population of 2,696,000 provided CMM incidence data for the years 2003-2017. Dermatologic office visit rates and skin biopsy rates were calculated using the Regional outpatient care database. All rates were age-standardized. Trends were described with the estimated average annual per cent change (EAAPC). Correlations were tested with the Spearman correlation coefficient.RESULTS: Incidence increased significantly. The increase was steeper for in situ CMM (EAAPC: men, 10.2; women, 6.9) followed by CMM <0.8 mm thick (9.1; 5.2), but the rates grew significantly for most subgroups of CMMs ≥0.8 mm thick. Mortality decreased significantly among women (-2.3) and non-significantly among men. For dermatologic office visit rate and skin biopsy rate the EAAPC were, respectively, 1.7 and 1.8 for men and 1.2 and 0.9 for women. Annual dermatologic office visit rate correlated with skin biopsy rate in both sexes. However, the proportion of skin biopsies out of dermatologic office visits was constant across the years (range: men, 0.182-0.216; women, 0.157-0.191).CONCLUSIONS: In Italy, the increasing CMM incidence trend is, at least in part, genuine. Overdiagnosis-if any-is due to an increased patient presentation at dermatologic offices and not to a lower dermatologic threshold to perform biopsy.

dermatology
Trends in the Diagnosis and Clinical Features of Melanoma in Situ (MIS) in US Men and Women: A Prospective, Observational Study

Erin X. Wei,Abrar A. Qureshi,Jiali Han,Tricia Y. Li,Eunyoung Cho,Jennifer Y. Lin,Wen-Qing Li

DOI: https://doi.org/10.1016/j.jaad.2016.05.011

IF: 15.487

2016-01-01

Journal of the American Academy of Dermatology

Abstract:Background: The incidence of melanoma in situ (MIS) is increasing, but little is known about its clinical and epidemiologic features.Objective: We sought to determine trends in diagnosis and clinical features of MIS.Methods: Incident cases of melanoma were collected prospectively from the Nurses' Health Study (1976-2010) and Health Professionals Follow-up Study (1986-2010).Results: MIS incidence increased from 2 to 42 per 100,000 person-year among women, and from 11 to 73 per 100,000 person-year among men, exceeding the rate of increase of invasive melanomas. Melanoma mortality initially increased during the follow-up period then plateaued. Men were more likely than women to develop in situ melanomas on the upper half of the body (P < .001). Invasive melanomas were diagnosed at a younger age than MIS (P < .001), and were more likely to be found on the lower extremities than MIS (P < . 001).Limitations: This is a strictly descriptive study without examination into mechanisms.Conclusion: We found epidemiologic and clinical differences for in situ and invasive melanomas, which support further examination into the variations in etiologic pathways. The lack of improvement in mortality despite the increase in detection of in situ relative to invasive lesions further highlights the need to improve invasive melanoma-specific clinical screening features.
The Incidence of Cutaneous Malignant Melanoma in Eastern Newfoundland and Labrador, Canada, from 2007 to 2015

Wayne Gulliver,Susanne Gulliver,Rebecca J. Power,Michelle Penney,David Lane

DOI: https://doi.org/10.1159/000519193

2021-10-05

Dermatology

Abstract:Background: The incidence of cutaneous malignant melanoma continues to increase worldwide and in Canada. It is unclear whether the increase in incidence and clinical characteristic trends of cutaneous malignant melanoma are similar in the province of Newfoundland and Labrador. Objective: The objective of this study is to examine the incidence and trends of cutaneous malignant melanoma in Eastern Newfoundland and Labrador. Methods: Patients aged 18 years or older diagnosed with cutaneous malignant melanoma were identified from the Eastern Health Authority's Cancer Registry. The diagnosis was confirmed by a pathologist via histological subtype. Patients were excluded if the diagnosis was unspecified, a nonmelanoma skin cancer or if there was a recurrence in the same lesion location. In total 298 patients diagnosed with cutaneous malignant melanoma from 2007 to 2015 were included in the analysis. Results: The total incidence increased from 4.1 to 15.6 cases/100,000 person-years, which represents a 283.0% increase from 2007 to 2015. The largest increases in incidence were seen in males and patients aged from 60 to 79 years. The most common lesion anatomical locations were the trunk in males and the lower extremity in females. The majority of cases had a Breslow thickness below 1.0 mm. Conclusion: The incidence of cutaneous malignant melanoma in Eastern Newfoundland and Labrador is increasing at a faster rate than in any other region in Canada. Health care providers should work to be aware of the clinical trends and risk factors associated with this disease to facilitate early detection and prevent morbidity. Dermatology

dermatology
Age group‐specific changes in keratinocyte cancer treatment rates in Australia, 2012– 2021: a retrospective cohort study based on MBS claims data

Catherine M Olsen,Nirmala Pandeya,Rachel E Neale,David C Whiteman

DOI: https://doi.org/10.5694/mja2.52293

2024-05-01

The Medical Journal of Australia

Abstract:Objectives To examine recent changes in the numbers of Medicare‐subsidised keratinocyte cancer excisions, particularly for younger people exposed to primary prevention campaigns since the early 1980s. Study design Retrospective cohort study; analysis of administrative data. Setting, participants Analysis of Medicare Benefits Schedule (MBS) claims data for procedures related to the diagnosis and treatment of keratinocyte cancer in Australia, 2012–2021. Main outcome measures Age‐standardised rates for MBS‐subsidised claims for first surgical squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) excisions, Mohs surgery, surgical excisions of benign lesions, skin biopsies, and cryotherapy or serial curettage of premalignant and malignant lesions, overall, and by sex, state/territory, and age group; average annual percentage change in rate for time intervals determined by joinpoint regression. Results In men, the age‐standardised rate of BCC/SCC excisions increased by 1.9% (95% confidence interval [CI], 1.4–2.4%) per year during 2012–2019 (from 2931 to 3371 per 100 000 men) and then declined by 3.8% (95% CI, 0.5–7.0%) per year during 2019–2021 (to 3152 per 100 000). In women, the age‐standardised rate increased by 2.2% (95% CI, 1.7–2.8%) per year during 2012–2019 (from 1798 to 2093 per 100 000 women); the decline to 1967 excisions per 100 000 women in 2021 was not statistically significant. BCC/SCC excision rates declined for men under 55 years of age (by 1.0–3.4% per year) and women under 45 years of age (by 1.7–2.3% per year). Age‐standardised biopsy rates increased during 2012–2021 in all age groups (by 2.8–6.9% per year). Conclusions Rates of MBS‐subsidised treatment for keratinocyte cancers increased during 2012–2019, but BCC/SCC treatment rates declined among younger Australians, who have probably been exposed to less sunlight than earlier generations because of public health interventions and population‐wide lifestyle changes related to technology use.

medicine, general & internal

Availability, Current issues, and Anticipation Training for Clinician-Patient Communication in Palliative Care: Learning and Doing or Learning by Doing?

Seasonal variation of anti‐PD‐1 outcome in melanoma—Results from a Dutch patient cohort

Trends in epidemiology and primary treatment of anal squamous cell carcinoma in the Netherlands (1990-2021)

P070 The epidemiology of skin cancer in Greater Manchester 2017–22: a retrospective cohort study using primary care records

Seasonal variations in the diagnosis of the top 10 cancers in Korea: A nationwide population-based study using a common data model

O13 42 590 fewer skin tumours diagnosed in England during the 2020 COVID pandemic: greatest reductions in melanoma in situ , stage I melanomas and basal cell carcinomas

Seasonal variation in effect of anti‐PD‐1 initiation on overall survival among patients with advanced melanoma

Time trends in incidence and mortality of cutaneous melanoma in Germany

Incidence of Nonmelanoma Skin Cancers in Alberta, Canada, From 2007 to 2018

Does sex matter? Temporal analyses of melanoma trends among men and women suggest etiologic heterogeneity

O09 Cutaneous squamous cell carcinoma survival in England 2004–2020: a national retrospective observational cohort study

Increasing melanoma incidence with unchanged mortality: more sunshine, better treatment, increased diagnostic activity, overdiagnosis or lowered diagnostic threshold?

Sinonasal mucosal melanoma in The Netherlands between 2001 and 2021: a clinical and epidemiological overview of 320 cases

Envelopes and Geometrical Covers of Side-Payment Games and Their Market Representations

Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy

Nationwide Trends in the Incidence of Melanoma and Non-melanoma Skin Cancers from 1999 to 2014 in South Korea

Global, regional and national incidence, mortality and disability‐adjusted life‐years of skin cancers and trend analysis from 1990 to 2019: An analysis of the Global Burden of Disease Study 2019

Patient presentation, skin biopsy utilization and cutaneous malignant melanoma incidence and mortality in northern Italy: Trends and correlations

Trends in the Diagnosis and Clinical Features of Melanoma in Situ (MIS) in US Men and Women: A Prospective, Observational Study

The Incidence of Cutaneous Malignant Melanoma in Eastern Newfoundland and Labrador, Canada, from 2007 to 2015

Age group‐specific changes in keratinocyte cancer treatment rates in Australia, 2012– 2021: a retrospective cohort study based on MBS claims data